Rhenman & Partners Asset Management AB Sells 17,500 Shares of Annexon, Inc. (NASDAQ:ANNX)

Rhenman & Partners Asset Management AB cut its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 3.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 542,500 shares of the company’s stock after selling 17,500 shares during the period. Rhenman & Partners Asset Management AB owned 0.51% of Annexon worth $2,783,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ANNX. FMR LLC boosted its stake in Annexon by 3.2% in the third quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after acquiring an additional 262,229 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Annexon by 11.6% in the 4th quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock valued at $28,456,000 after purchasing an additional 576,625 shares during the period. State Street Corp boosted its position in shares of Annexon by 116.6% in the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after purchasing an additional 2,068,294 shares during the last quarter. Candriam S.C.A. grew its stake in shares of Annexon by 15.6% during the fourth quarter. Candriam S.C.A. now owns 2,534,230 shares of the company’s stock worth $13,001,000 after purchasing an additional 341,431 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Annexon by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company’s stock valued at $11,142,000 after purchasing an additional 27,843 shares during the last quarter.

Annexon Trading Down 7.7 %

ANNX stock opened at $1.69 on Friday. Annexon, Inc. has a 1-year low of $1.66 and a 1-year high of $7.85. The business’s 50-day moving average price is $2.81 and its two-hundred day moving average price is $4.82. The firm has a market cap of $185.41 million, a PE ratio of -1.61 and a beta of 1.24.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ANNX shares. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.